Table 5.

Regression of percent change in HtTKV versus change in urine biomarkers by study group (placebo and pravastatin)

Variable	Group	Model	Estimate ± SEM	95% Confidence Limits	P Value
Citrate, mmol/mmol creatinine	Placebo	Unadjusted	−0.007±0.004	−0.02 to 0.001	0.09
		Model 1	−0.008±0.004	−0.02 to −0.004	0.04
		Model 2	−0.008±0.004	−0.02 to −0.003	0.04
PGF2α, µg/mmol creatinine	Placebo	Unadjusted	−0.007±0.003	−0.01 to −0.001	0.03
		Model 1	−0.006±0.003	−0.01 to −0.001	0.03
		Model 2	−0.006±0.003	−0.01 to −0.001	0.03
8-HETE, µg/mmol creatinine	Pravastatin	Unadjusted	0.14±0.06	0.01 to 0.27	0.03
		Model 1	0.17±0.06	0.05 to 0.29	0.01
		Model 2	0.18±0.06	0.06 to 0.30	0.01
9-HETE, µg/mmol creatinine	Pravastatin	Unadjusted	0.15±0.07	0.01 to 0.29	0.03
		Model 1	0.22±0.06	0.09 to 0.35	0.001
		Model 2	0.23±0.06	0.11 to 0.36	<0.001
11-HETE, µg/mmol creatinine	Pravastatin	Unadjusted	0.18±0.11	−0.05 to 0.40	0.11
		Model 1	0.23±0.10	0.01 to 0.44	0.04
		Model 2	0.26±0.10	0.04 to 0.47	0.02

Results are presented as the estimate±SEM with 95% confidence limits. Regression models included the following: model 1, adjusted for age and sex; and model 2, adjusted for age, sex, log-transformed GFR, and systolic BP. HtTKV, height-corrected total kidney volume; HETE, hydroxyeicosatetraenoic acid.